Henan Newland Pharmaceutical Co., Ltd. was established in September 2005 with a registered capital of RMB 133.36 million. It is mainly engaged in the R&D, production and sales of pharmaceutical intermediates and APIs, and is a globally important producer of L-p-hydroxyphenylglycine, a synthetic side chain of amoxicillin. The company has led or participated in the formulation of industry standards for products including L-p-hydroxyphenylglycine and p-toluenesulfonic acid, and is one of the second batch of "Specialized, Refined, Differentiated and Innovative" (SRDI) enterprises in Henan Province.

Henan Newland Pharmaceutical Co., Ltd. comprises two plant areas: the South Plant is located on the east side of the south section of Weiwu Avenue, Changge Industrial Cluster Area, and the North Plant is located on the north side of the east section of Huangjin Avenue, Dazhou Recycled Metals Circular Industrial Cluster Area, Changge City. In February 2023, Henan Newland Pharmaceutical Co., Ltd. was included in the "Notice of the Office of the Department of Ecology and Environment of Henan Province on Announcing the List of Enterprises Implementing Cleaner Production Audits in Henan Province in 2023" (Yuhuanban [2023] No. 11). In accordance with the "Measures for Cleaner Production Audit" and the "Implementation Rules for Cleaner Production Audits in Henan Province" (Yufagaihuanzi [2018] No. 161), the pollutant discharge of Henan Newland Pharmaceutical Co., Ltd. before the cleaner production audit is hereby publicly announced.